Most Read Articles
Stephen Padilla, 23 hours ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 3 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
6 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
15 Jun 2018
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.

Elagolix safe, effective for heavy menstrual bleeding

16 Oct 2017

Elagolix is safe and effective for reducing heavy menstrual bleeding in females with fibroids, a new dose-ranging, multiple-cohort study has shown.

Investigators randomized 271 females (mean age 41.8 years) to receive elagolix alone (n=160), elagolix and an add-back therapy (n=61) or placebo (n=50). The primary study outcome was the mean and percentage change in menstrual blood loss (MBL).

Females who received elagolix had significantly larger reductions in MBL from baseline to last complete treatment cycle compared with those who received placebo (p<0.01). Inclusions of add-back on therapies also reduced the MBL compared with placebo, but in magnitudes lower than those in patients who took elagolix only.

Elagolix also exerted a dose-dependent suppressive effect on heavy menstrual bleeding, with those receiving the 300 mg twice-daily doses experiencing the most suppression. Indeed, even if the total daily dose was the same, twice-daily dosing resulted in similar or greater MBL reductions.

Majority (84.4 to 96.8 percent) of females in the elagolix group had menstruation within 90 days of the last dose, resulting in a median range of time to return to menstruation of 25 to 30 days. In the placebo group, 93.3 to 100 percent of the females returned to menstruation within 90 days, and the median range of time was 11 to 19 days.

“These results provide a rationale for phase IIb and III clinical trials of longer duration to further evaluate the safety and efficacy of elagolix with add-back regimens,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 23 hours ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 3 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
6 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
15 Jun 2018
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.